Publications
Detailed Information
Serum fibroblast growth factor-21 concentration is associated with residual renal function and insulin resistance in end-stage renal disease patients receiving long-term peritoneal dialysis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Han, Seung Hyeok | - |
dc.contributor.author | Choi, Sung Hee | - |
dc.contributor.author | Cho, Bong Jun | - |
dc.contributor.author | Lee, Yenna | - |
dc.contributor.author | Park, Young Joo | - |
dc.contributor.author | Lee, Hong Kyu | - |
dc.contributor.author | Han, Dae Suk | - |
dc.contributor.author | Jang, Hak C. | - |
dc.contributor.author | Park, Kyong Soo | - |
dc.contributor.author | Kim, Young-Bum | - |
dc.contributor.author | Kang, Shin-Wook | - |
dc.contributor.author | Moon, Min Kyung | - |
dc.contributor.author | Lim, Soo | - |
dc.date.accessioned | 2012-06-27T08:28:27Z | - |
dc.date.available | 2012-06-27T08:28:27Z | - |
dc.date.issued | 2010-11 | - |
dc.identifier.citation | METABOLISM-CLINICAL AND EXPERIMENTAL; Vol.59 11; 1656-1662 | ko_KR |
dc.identifier.issn | 0026-0495 | - |
dc.identifier.uri | https://hdl.handle.net/10371/77650 | - |
dc.description.abstract | Fibroblast growth factor-21 (FGF-21) is a new metabolic regulator, which is related to antiobesity and insulin sensitivity in vivo. However, the clinical implication of FGF-21 is poorly understood. To investigate whether FGF-21 may play a role as a metabolic regulator in patients with end-stage renal disease, we measured serum concentrations of FGF-21, inflammatory markers, and metabolic parameters in healthy people (n = 63) and nondiabetic patients receiving peritoneal dialysis (PD, n = 72). The patients were treated with angiotensin receptor blocker for 6 months, and the changes in FGF-21 concentration and metabolic parameters were assessed. Compared with controls, serum FGF-21 concentration was 8 times higher in patients undergoing PD (754.2 +/- 463.5 vs 86.9 +/- 60.2 pg/mL, P < .001). In controls, only lipid parameters correlated positively with FGF-21 concentration. In contrast, inflammatory markers (interleukin-6, fibrinogen, high-sensitivity C-reactive protein) and homeostasis model assessment of insulin resistance (HOMA-IR) correlated positively and residual renal function correlated inversely with serum FGF-21 concentration in PD patients. In a multivariate analysis adjusting these factors, residual renal function, HOMA-IR, and fibrinogen concentration were independent determinants of serum FGF-21 concentration. After 6-month angiotensin receptor blocker treatment, serum FGF-21 concentration declined significantly by 13% and HOMA-IR and inflammatory markers improved in PD patients. These findings suggest that FGF-21 may play a role in insulin resistance in patients with end-stage renal disease. (C) 2010 Elsevier Inc. All rights reserved. | ko_KR |
dc.description.sponsorship | This work was supported by grants from the Seoul R&BD
program to Choi SH, Republic of Korea (10526). | ko_KR |
dc.language.iso | en | ko_KR |
dc.publisher | W B SAUNDERS CO-ELSEVIER INC | ko_KR |
dc.title | Serum fibroblast growth factor-21 concentration is associated with residual renal function and insulin resistance in end-stage renal disease patients receiving long-term peritoneal dialysis | ko_KR |
dc.type | Article | ko_KR |
dc.contributor.AlternativeAuthor | 한승혁 | - |
dc.contributor.AlternativeAuthor | 최성희 | - |
dc.contributor.AlternativeAuthor | 조봉준 | - |
dc.contributor.AlternativeAuthor | 이예나 | - |
dc.contributor.AlternativeAuthor | 임수 | - |
dc.contributor.AlternativeAuthor | 박영주 | - |
dc.contributor.AlternativeAuthor | 문민경 | - |
dc.contributor.AlternativeAuthor | 이홍규 | - |
dc.contributor.AlternativeAuthor | 강신욱 | - |
dc.contributor.AlternativeAuthor | 한대석 | - |
dc.contributor.AlternativeAuthor | 김영범 | - |
dc.contributor.AlternativeAuthor | 장학철 | - |
dc.contributor.AlternativeAuthor | 박경수 | - |
dc.identifier.doi | 10.1016/j.metabol.2010.03.018 | - |
dc.citation.journaltitle | METABOLISM-CLINICAL AND EXPERIMENTAL | - |
dc.description.citedreference | Stein S, 2009, DIABETES CARE, V32, P126, DOI 10.2337/dc08-1054 | - |
dc.description.citedreference | Coskun T, 2008, ENDOCRINOLOGY, V149, P6018, DOI 10.1210/en.2008-0816 | - |
dc.description.citedreference | Izumiya Y, 2008, FEBS LETT, V582, P3805, DOI 10.1016/j.febslet.2008.10.021 | - |
dc.description.citedreference | Galman C, 2008, CELL METAB, V8, P169, DOI 10.1016/j.cmet.2008.06.014 | - |
dc.description.citedreference | Arner P, 2008, FEBS LETT, V582, P1725, DOI 10.1016/j.febslet.2008.04.038 | - |
dc.description.citedreference | Zhang X, 2008, DIABETES, V57, P1246, DOI 10.2337/db07-1476 | - |
dc.description.citedreference | Suzuki M, 2008, MOL ENDOCRINOL, V22, P1006, DOI 10.1210/me.2007-0313 | - |
dc.description.citedreference | Kharitonenkov A, 2008, BIODRUGS, V22, P37 | - |
dc.description.citedreference | Chen WW, 2008, EXP CLIN ENDOCR DIAB, V116, P65, DOI 10.1055/s-2007-985148 | - |
dc.description.citedreference | Inagaki T, 2007, CELL METAB, V5, P415, DOI 10.1016/j.cmet.2007.05.003 | - |
dc.description.citedreference | Badman MK, 2007, CELL METAB, V5, P426, DOI 10.1016/j.cmet.2007.05.002 | - |
dc.description.citedreference | Martins C, 2007, J RENAL NUTR, V17, P132, DOI 10.1053/j.jrn.2006.07.004 | - |
dc.description.citedreference | Kharitonenkov A, 2007, ENDOCRINOLOGY, V148, P774, DOI 10.1210/en.2006-1168 | - |
dc.description.citedreference | de Vinuesa SG, 2006, J AM SOC NEPHROL, V17, pS206, DOI 10.1681/ASN.2006080916 | - |
dc.description.citedreference | Wang AYM, 2006, KIDNEY INT, V69, P1726, DOI 10.1038/sj.ki.5000382 | - |
dc.description.citedreference | Kharitonenkov A, 2005, J CLIN INVEST, V115, P1627, DOI 10.1172/JCI23606 | - |
dc.description.citedreference | Zoccali C, 2004, NEPHROL DIAL TRANSPL, V19, P67, DOI 10.1093/ndt/gfh1059 | - |
dc.description.citedreference | Lin SH, 2003, AM J KIDNEY DIS, V42, P774, DOI 10.1053/S0272-6386(03)00844-8 | - |
dc.description.citedreference | Zoccali C, 2003, J INTERN MED, V254, P132 | - |
dc.description.citedreference | Shinohara K, 2002, J AM SOC NEPHROL, V13, P1894, DOI 10.1097/01.ASN.0000019900.87535.43 | - |
dc.description.citedreference | MAK RHK, 1992, NEPHRON, V61, P377 | - |
dc.description.citedreference | MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412 | - |
dc.description.citedreference | DEFRONZO RA, 1981, J CLIN INVEST, V67, P563 | - |
dc.description.citedreference | WATSON PE, 1980, AM J CLIN NUTR, V33, P27 | - |
dc.description.tc | 0 | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.